SMITH & NEPHEW PLC -SPON ADR
SNNNYSETrading Snapshot
- Day Range
- $465.15 β $479.68
- 52-Week Range
- $991.00 β $1,426.50
- Volume
- $2.35B
- Avg Volume
- $2.53B
- Shares Outstanding
- 840.5M
- Next Earnings
- Nov 25, 2026
Fundamentals Snapshot
- Annual Revenue
- $6.16B
- Last Q Revenue
- $3.10B
- P/E Ratio
- 17.6
- P/S Ratio
- 1.8x
- EPS (TTM)
- $0.74
- Dividend Yield
- 2.98%
- Dilution (1yr)
- β0.8%
Why Investors Own SNN
- βHigh-growth profile β revenue up +13.3% YoY with expanding US Equity exposure.
- βHealthy economics β 72% gross margin and 16% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
SMITH & NEPHEW PLC -SPON ADR
SNNAbout SMITH & NEPHEW PLC -SPON ADR
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Price Target
βLatest News & Updates
SMITH & NEPHEW PLC -SPON ADR tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift SNN price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
SMITH & NEPHEW PLC -SPON ADR announces new agreement to expand its footprint
The move broadens the companyβs reach and could add incremental revenue over the next year.